Guiding principles for clinical use of fosrolapitant and palonosetron hydrochloride for injection in the prevention of anti-tumor induced nausea and vomiting
Expert Committee on Safety Management of Antitumor Therapy,Chinese Society of Clinical Oncology
Expert Committee on Supportive and Rehabilitation Therapy for Tumors,Chinese Society of Clinical Oncology
ZHANG Li
LIANG Jun
PAN Hongming
LUO Suxia
WANG Jiejun
YANG Fan
LIAO Feng
CHEN Yinxia
MA Jun
QIN Shukui
Abstract：TAnti-tumor therapy(mainly including drug therapy)often causes the nausea and vomiting,which not only brings obvious discomfort to cancer patients,increases their psychological and mental burden,but also affects the compliance of anti-tumor treatment and the overall therapeutic efficacy.Those nausea and vomiting symptoms often last for a quite long time,usually persisting for more than 120 hours after administration of anti-tumor drugs.However,now clinical commonly used antiemetic drugs have a shorter half-life time,making it difficult to cover the entire risk period of nausea and vomiting with a single anti-tumor treatment cycle.Thus there is an urgent as well as huge unmet need for longer acting,more convenient and safe drugs,to facilitate whole-process management of anti-tumor therapy induced nausea and vomiting in clinical practice.Fosrolapitant and palonosetron hydrochloride for injection is a novel dual-channel,ultra-long acting antiemetic drug approved by the Chinese National Medical Products Administration(NMPA)on May 27,2025,for the effective prevention of acute and delayed nausea and vomiting caused by the adult highly emetic chemotherapy(HEC)drug or regimen.That drug targets both the neurokinin-1(NK-1)receptor and the 5-hydroxytryptamine 3(5-HT3)receptor,achieving strong and dual blockade of those two emetic targets in same time.Its half-life time is up to 188 hours,thus a single administration can cover the acute,delayed,and ultra-delayed phases of nausea and vomiting related to a single anti-cancer treatment cycle.In order to standardize the clinical application of fosrolapitant and palonosetron hydrochloride for injection,Expert Committee on Safety Management of Antitumor Therapy and Expert Committee on Supportive and Rehabilitation Therapy for Tumors,Chinese Society of Clinical Oncology(CSCO)jointly organized an expert group.Based on the latest research evidence and clinical experience,they repeatedly deliberated to formulate these guidelines for reference by physicians.
Keywords：anti-tumor therapynauseavomitingfosrolapitant and palonosetron hydrochloride injection
Publication Date：2025-12-28
Online Publishing Date：2026-01-12(First online date of this platform, not the publication date of the document)
Pages：6( 1213-1218 )